CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

NCT04303247 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoma Refractory
B-cell Lymphoma Recurrent

Interventions

BIOLOGICAL: CD19 and CD22 targeted CAR-T cells

Sponsor

Xinqiao Hospital of Chongqing

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]